Ocugen, Inc., a leader in gene therapies for blindness diseases, has announced a licensing agreement with Kwangdong Pharmaceutical Co., Ltd. for the exclusive rights to OCU400, a novel modifier gene therapy for retinitis pigmentosa, in Korea. The agreement includes upfront fees and near-term development milestone payments totaling up to $7.5 million, with potential sales milestones of $180 million or more in the first ten years of commercialization. Ocugen will also receive a 25% royalty on net sales, while manufacturing and supplying OCU400 under a supply agreement. With an estimated 7,000 individuals affected by retinitis pigmentosa in Korea, this partnership is set to make a significant impact in the field of ophthalmic gene therapy. Ocugen is advancing OCU400 through Phase 3 clinical development, with a U.S. Biologics License Application filing targeted for 2026.